Polyrizon expands U.S. patent claims for its intranasal drug delivery platform, boosting IP protection.

Polyrizon Ltd. has submitted amended claims to expand the scope of its U.S. patent application for its intranasal drug delivery platform. The expanded claims now cover not only the core mucoadhesive composition but also drug delivery systems and methods designed to improve drug effectiveness by increasing residence time and mucosal contact. This move strengthens Polyrizon's global intellectual property portfolio and enhances the potential applicability of its technology across various therapeutic areas. The platform aims to improve drug absorption and efficacy through prolonged retention and controlled film formation on mucosal surfaces.